E164 - Best of CSF 2023 with Elena Parvez

Dr. Elena Parvez is a surgical oncologist and Assistant Professor in the Department of Surgery. Her clinical expertise and research interests are in breast cancer. She is exploring breast cancer outcomes in refugees to Canada who have breast cancer. She has received funding from Canadian Institutes of Health Research (CIHR) to conduct a trial which identifies a strategy to avoid post-neoadjuvant radiation therapy in patients with locally advanced breast cancer who have a complete response to neoadjuvant chemotherapy.She presented this work at the “Best of CSF Research 2023” session last year.Join us at the upcoming CSF in Winnipeg!https://www.canadiansurgeryforum.com/Links:Adjuvant radiation therapy among immigrant and Canadian-born/long-term resident women with breast cancer. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718225/https://experts.mcmaster.ca/display/parveze https://www.canadiansurgeryforum.com/ Well the summer has come and gone and we’re back into the swing of things! We’re really excited that in a couple of weeks, many surgeons from across Canada will be meeting for our largest national conference, the Canadian Surgical Forum. This year it is in the lovely city of Winnipeg. It’s a time to catch up with friends and colleagues across the country, and to hear the amazing work that’s been going on. This is a teaser for the type and calibre of work that goes on at CSF. Dr. Elena Parvez presented this work last year at the best research of CSF 2023 session. Dr. Parvez is an assistant professor of surgery at McMaster University in Hamilton. Her clinical practice is in surgical oncology. In this episode, she presented her work on adjuvant radiation therapy among immigrant and Canadian-born women with breast cancer. We look forward to meeting many of our listeners at CSF this year and we’ll be recording some interviews live at CSF. We’d love to hear your feedback and suggestion for content for the upcoming year. As always, you can also send your thoughts to [email protected]. 

There are no comments yet.

Please log in to write the first comment.